Background/Aims: Human adipose-derived stem cells (hADSCs) are a potential therapeutic option for clinical applications because of their ability to produce cytokines and their capacity for trilineage differentiation. To date, few researchers have investigated the effects of hADSCs on natural ovarian aging (NOA). Methods: An NOA mouse model and human ovarian granule cells (hGCs) collected from individuals with NOA were prepared to assess the therapeutic effects and illuminate the mechanism of hADSCs in curing NOA. Enzyme-linked immunosorbent assay was used to detect the serum levels of sex hormones and antioxidative enzymes. The proliferation rate and marker expression level of hGCs were measured by flow cytometry (FACS). Cytokines were measured by a protein antibody array methodology. Western blot assays were used to determine the protein expression levels of SIRT1 and FOXO1. Results: Our results showed that hADSCs displayed therapeutic activity against ovarian function in an NOA mouse model, increasing the proliferation rate and marker expression level of hGCs. Furthermore, the yields of hADSC-secreted HGF and bFGF were higher than those of other growth factors. FACS showed that combination treatment with the growth factors HGF and bFGF more strongly promoted proliferation and inhibited apoptosis in hGCs than HGF or bFGF treatment alone. FACS and ELISA revealed that the combination treatment with both growth factors inhibited oxidative stress more forcefully than treatments with only one of these growth factors. In addition, protein assays demonstrated that combination treatment with both growth factors suppressed oxidative stress by up-regulating the expression of SIRT1
hADSCs Improves Function of Ovary with Natural Aging medium), 100 mg/ml of streptomycin sulfate (Thermo, USA), and 1X GlutaMAX (Thermo, USA). The culture medium was changed every other day in all experiments.
Establishment of an NOA mouse model
Natural aging female C57BL/6 mice (SPF class, 12-14 months old) and young, fertile female C57BL/6 mice (SPF class, 3-5 months old) were provided by Nanjing Medical University with approval from the Institutional Animal Care and Use Committee in accordance with institutional guidelines. The mice were bred at a temperature of 28 ± 2°C with a 12-hour light/dark cycle. Mouse vaginal smears were taken to determine the estrous cycle at 9:00 am daily. Only aging mice with disorganized estrous cycles and young mice with normal estrous cycles were chosen. Aging mice were randomly distributed into the control group and treatment group (n = 15 per group). Young mice were set as the normal control group (n = 15 per group).
Co-culture of hGCs with HGF and bFGF and injection of these cells into NOA mouse ovaries
A portion of the abovementioned hGCs were divided into the following groups: the HGF co-culture group (one-fold dose: 20 ng/ml, Sigma), bFGF co-culture group (one-fold dose: 100 ng/ml, R&D Systems), HGF and bFGF combination co-culture group and PBS co-culture control group. After the hGCs were cocultured with growth factors or PBS for 7 days, they were used for further experiments. The NOA mouse model was divided into an HGF-injected group (one-fold dose: 0.2 μg/ml, Sigma), a bFGF-injected group (one-fold dose: 1 μg/ml, R&D system), an HGF and bFGF combination-injected group and a saline-injected control group. Four weeks after growth factors or PBS was injected into the ovary of the mouse model, mice in each group were sacrificed to evaluate the follicle number by hematoxylin and eosin assays.
Assessment of ovarian function by comparison of ovarian follicle counts
After cell transplantation, the mice (with transplanted cells or no transplantation) were euthanized from 0 to 4 weeks. ovaries from both sides were removed, fixed in 10% formalin, paraffin embedded, serially sectioned into 5 mm thick sections, mounted in order on glass microscope slides, and stained with hematoxylin and eosin (HE). Follicles from four stages (primordial, primary, secondary and antral follicles) were detected and classified. The ratio of the number of follicles from the ovaries on both sides at four stages was calculated and compared between each group (per group, n = 10). Three representative sections from each ovary were selected. Only follicles containing an oocyte were counted to avoid counting any follicle twice. The experiments were repeated three times, the results are presented as fold change ± SD, and p < 0.05 was considered significantly different.
Immunofluorescence staining
The following primary antibodies were used to characterize ovarian tissues: anti-human BrdU (Abcam, USA), anti-human HGF (Abcam, USA), anti-human bFGF (Abcam, USA), anti-human EGF (Abcam, USA), antihuman IGF-1 (Abcam, America) and anti-human BDNF (Abcam, USA). For the staining procedure, ovarian sections were fixed in 4% (w/v) paraformaldehyde (PFA; Sigma, USA) at room temperature for 10 min, and then, the sections were washed three times with phosphate-buffered solution (PBS) for 5 min, permeated with 0.1% Triton X-100 (Sigma, USA)/PBS on ice for 10 min, and blocked with fresh 4% bovine serum albumin (BSA; Sigma, USA)/PBS at room temperature for 30 min. The treated cells were washed three times with PBS for 5 min and then incubated with primary antibodies overnight at 4°C. After rinsing with PBS for 5 min, the cells were stained with Cy2-or FITC-conjugated secondary antibodies (Jackson Immuno Research, West Grove) in the dark at room temperature for 30 min. The stained cells were mounted with 4',6-diamidino-2-phenylindole (DAPI; Vector Lab, USA) after they were washed with PBS for 5 min, and then, the stained cells were photographed under a fluorescence microscope (Olympus, Japan). 
FACS analysis
hADSCs and hGCs were digested separately by trypsin-EDTA for 3 min and gently blown into single cells, which were fixed and permeated with a Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD, USA) following the manufacturer's instructions. The hADSCs were then stained with PE-conjugated antihuman CD105 (BD, USA), anti-human CD34 (BD, USA), anti-human CD29 (BD, USA), anti-human-CD73 (BD, USA), and anti-human CD90 (BD, USA) antibodies or their corresponding isotype control for 30 min at 4°C as described above. The hGCs were then stained with PE-or FITC-conjugated anti-human ki67 (Abcam, USA), anti-human AMH (Thermo, USA), anti-human FSHR (Thermo, USA), anti-human FOXL2 (Thermo, USA), anti-human CYP19A1 (Abgent, USA), anti-human CD8 (BD, USA), anti-human Annexin V (Abcam, USA) and anti-human ROS (Abcam, USA) antibodies or their corresponding isotype control for 30 min at 4°C as described above. These stained cells were analyzed on a fluorescence-activated cell sorter (Beckman, USA). The experiments were repeated three times, the results are presented as fold change ± SD, and p < 0.05 was considered significantly different.
Enzyme-linked immunosorbent assay (ELISA) analysis
Plasma from the NOA mouse model was harvested to evaluate the expression levels of E2, AMH or FSH by using an ELISA kit (MyBioSource, USA) according to the manufacturer's instructions. Briefly, a 50 μl serum sample was added to each well. The test plate was wrapped with membrane and incubated for 30 min at 37°C. Thereafter, the wells of the plate were dried and washed with wash buffer 5 times (10 s per time). Then, 50 μl of HRP-conjugate reagent was added to each sample well and incubated for 60 min at 37°C. The samples were washed with wash buffer 5 times (10 s per time). Subsequently, 50 μl of substrate A solution followed by 50 μl of substrate B solution were added and incubated for 15 min at 37°C. Then, 50 μl of stop solution was added to each control and sample well. Finally, the light absorbance was measured and recorded by a spectrophotometer (Varian Company, Australia).
Activity measurements with Superoxide Dismutase Assay Kit, Catalase Assay Kit, Glutathione Reductase Assay Kit, and Glutathione Peroxidase Assay Kit
The mouse ovaries and hGCs used for measuring SOD, CAT, GPx, and glutathione reductase (GR) activities were homogenized in Na 2 PO 4 KCl (30 mM Na 2 PO 4 , 14 mM KCl, pH = 7.4). We measured SOD, CAT, GPx, and GR activities using the corresponding assay kits by Cayman Chemical. SOD activity was measured using an SOD assay kit. The kit utilized a tetrazolium salt for the detection of the dismutation of superoxide radicals generated by xanthine oxidase and hypoxanthine that react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride to form a formazan dye that was assayed spectrophotometrically at 492 nm at 37°C. SOD activity is expressed as U/mg. CAT is an enzyme that can degrade peroxides, including hydrogen peroxide (H 2 O 2 ), and its activity assessment was based on establishing the rate of H 2 O 2 degradation spectrophotometrically at 240 nm at 25°C. CAT activity was calculated in terms of micromoles of H 2 O 2 consumed per minute per milligram of protein, and the result is expressed as U/mg. The GR kit measured the rate of oxidation of NADPH to NADP+, which was accompanied by a decrease in absorbance at 340 nM. One unit of GR is defined as the amount of enzyme that would cause the oxidation of 1.0 nmol of NADPH to NADP+ per minute at 25°C. SOD activity is expressed as nmol/min/ml. GPx activity was measured directly via a GR reaction. Oxidized glutathione produced by organic hydroperoxide reduction of GPx was recycled to its reduced state by GR and NADPH. NADPH to NADP+ oxidation is accompanied by decreased absorbance at 340 nm, which was directly proportional to GPx activity in the sample. One unit of GPx is defined as the amount of enzyme that would cause the oxidation of 1.0 nmol of NADPH to NADP+ per minute at 25°C. The result is expressed as nmol/min/ml.
Gene silencing with RNA interference SIRT1 siRNA (Thermo Fisher, USA) was transfected into hGCs at a final concentration of 40 nM to silence SIRT1 using Dharmafect 1 (Dharmacon, cat. T-2001-02) transfection reagent following the manufacturer's instructions. Cells were seeded in a 12-well plate before transfection so that they were 50% confluent for transfection. We used 2 μl of transfection reagent, 2 μl of 20 mM siRNA solution, and 4×10 4 cells in 1 ml of culture medium. The efficacy of gene silencing was checked by Western blot analysis and found to be optimal at 72 h.
Results

hADSCs restored ovarian function in an NOA mouse model
First, to evaluate the effects of hADSC treatments on ovarian function in an NOA mouse model, fluorescence-activated cell sorting (FACS) was used to characterize the hADSCs. Our results showed that the cell surface markers CD90, CD73 and CD29 were highly expressed and that the surface markers CD105 and CD34 were minimally expressed in hADSCs (Fig. 1A) . hADSCs are multipotent mesenchymal stem cells, as indicated by their ability to differentiate into adipocytes, chondroblasts and osteoblasts (Fig. 1B) . After hADSCs were injected into the ovaries of NOA mice, HE-stained ovarian tissues showed that hADSCs could restore the follicle number to 83% primordial follicles, 88% primary follicles, 84% secondary follicles, and 75% antral follicles significantly at week four compared to the control group ( Fig. 2A , 2B, 2C and 2D). The hormone level in plasma in each group was determined after hADSC transplantation. hADSCs rescued the level of E2 and AMH to normal levels gradually from weeks one to four ( Fig. 2E and 2G ). In addition, the level of FSH significantly decreased to normal levels compared to the control group (Fig. 2F) . Overall, hADSCs exhibited a powerful ability to restore ovarian function in an NOA mouse model. 
hADSCs increased the proliferation rate and marker expression levels of hGCs
To investigate the therapeutic effects of hADSCs on patients with NOA in the clinic, we collected hGCs from the young group (n = 19) and the NOA group (n = 15) in our reproductive center to examine the effects of cell proliferation after co-culture with hADSCs ( Fig. 3A) . hGC markers (AMH, FSHR, FOXL2 and CYP19A1) and ki67 antibody (a cell proliferation marker) were used to estimate the effects of hADSCs by FACS analysis. Our results showed that hADSCs caused a greater increased the ki67 + AMH + cell number in the NOA group (61%) than in the PBS administration group (30%) compared to the young group, as shown in Fig.  3B . In Fig. 3C , the FACS assay results demonstrated that hADSCs caused a greater increase in the ki67 + FSHR + cell number in the NOA group (77%) than in the PBS administration group (35%) compared to the young group. In Fig. 3D , our results revealed that hADSCs caused a greater increase in the ki67
+ cell number in the NOA group (72%) than in the PBS administration group (35%) compared to the young group. In addition, the FACS assay results showed that hADSCs caused a greater increase in the ki67
+ cell number in the NOA group (95%) than in the PBS co-cultured group (46%) compared to that in the young group, as shown in Fig. 3E .
In summary, hADSCs exhibited powerful recovery effects for natural senescent hGCs.
Expression levels of HGF and bFGF derived from hADSCs were higher than those of other growth factors
To investigate the mechanism by which transplanted hADSCs have a restorative effect on an NOA mouse model, the supernatant was collected from three hADS cell lines derived from three different donors (1 male, 2 female) and a control group (293T cell line). Then, a cytokine antibody array (growth factors = 52) was utilized to evaluate this diversity. Our analytical data elucidated that the number of growth factors secreted from hADSCs exceeded that secreted from cells in the control group (Fig. 4A ). There were twenty-three growth Fig. 2 . hADSCs improved the function of an NOA mouse model. a. The number of primordial follicles was counted over four weeks after hAD-SC transplantation. b. The number of primary follicles was counted over four weeks after hADSC transplantation. c. The number of secondary follicles was counted over four weeks after hADSC transplantation. d. The number of antral follicles was counted over four weeks after hADSC transplantation. e. The levels of E2 was measured by ELISA over four weeks after hAD-SC transplantation. f. The levels of FSH was measured by ELISA over four weeks after hADSCs transplantation. g. The levels of AMH was measured by ELISA over four weeks after hADSC transplantation. All of experiments were carried three times; the error bars indicate the SD; *, p<0.05; **, p<0.01; *** p<0.001 (compared with the NOA group). NOA = natural ovary aging, hADSC = human adipose-derived stem cell. factors secreted from hADSCs that had significantly higher levels than those secreted from cells in the control group (p < 0.05) (Fig. 4B ). In accordance with the standard criteria that the fold change is greater than or equal to eight and with statistical significance (p < 0.01), five growth factors were selected: BDNF, EGF, bFGF, HGF, and IGF-1 (Fig. 3B) . The secretion levels of bFGF and HGF were obviously higher than those of other growth factors (Fig. 4C ). After hADSCs were transplanted into the NOA mouse model for four weeks, immunofluorescence assay revealed that bFGF and HGF, but not BDNF, IGF-1 and EGF, were expressed in the ovary of the NOA mouse model (Fig. 4D ). Taken together, these results suggest that bFGF and HGF may play a vital role in improving ovary function in a natural aging mouse model.
Combination treatment with HGF and bFGF improved the proliferation rate of hGCs and increased the follicle number in NOA mice
To examine the effects of HGF and bFGF on cell proliferation and apoptosis, hGCs were separately co-cultured with HGF and bFGF for 7 days (Fig. 5A) . FACS assay was employed to quantitatively assess cell viability. Our results showed that the proliferation rate of hGCs was increased to 24% in the HGF group and 26% in the bFGF group, and these rates were higher than that of the untreated group (9%) compared to that of the young mouse group (63%) in Fig. 5B . FACS assay also indicated that the combination treatment with both growth factors (HGF and bFGF) caused a greater increase in the proliferation rate of hGCs (reaching 47%) than the single growth factor treatments (Fig. 5B) . Similarly, the apoptosis assay results indicated that a single growth factor decreased the rate of apoptosis to 29% in the HGF group and 27% in the bFGF group, and these rates were lower than that in the untreated group (55%) compared to that in the young mouse group (8%), as shown in Fig. 5C . The 
combination treatment with both growth factors (HGF and bFGF) significantly and more strongly inhibited the rate of apoptosis (13%) than the single growth factor treatments (Fig.  5C ). Furthermore, after HGF and bFGF were separately injected into the ovary of a natural aging mouse model, our results showed that treatment with a single growth factor increased the number of follicles only slightly, to 37% in the HGF group and 33% in the bFGF group, slightly more than that in the natural aging group (21%) compared to that in the young mouse group (Fig. 5D ). When the combination treatment with HGF and bFGF was injected into the ovary of the NOA mouse model, we found that the combination treatment with both growth factors increased the number of follicles to 69%, which was higher than the number of follicles in the single growth factor group compared to that in the young mouse group (Fig.  5D) .
The effects of a five-fold dose of HGF and bFGF injected into the ovary of the NOA mouse model were also estimated (Fig. 6A) . Similar to the one-fold dose group, our results showed that the proliferation rate of hGCs was increased to 21% in the HGF group and 22% in the bFGF group, higher than that in the untreated group (8%) compared to that in the youthful mice group (60%), as shown in Fig. 6A . The FACS assay results indicated that the combination treatment (HGF and bFGF) increased the proliferation rate of hGCs more (45%) than the single growth factor treatments (Fig. 6B ). With regard to the level of apoptosis, our results indicated that high-dose growth factor treatment curbed the apoptosis rate to 31% in the HGF group, 32% in the bFGF group and 15% in the combination treatment group (HGF Fig. 6 . Therapeutical effects of growth factor combination group with five-fold dose on hGCs from NOA were similar to those of one-fold dose. a. A schematic diagram of bFGF and HGF in five-fold dose co-cultured with hGCs. b. A combination of bFGF and HGF in five-fold dose improved the proliferation in hGCs as same as in one-fold dose. c. A combination of bFGF and HGF in five-fold dose inhibited the apoptosis in hGCs as same as in one-fold dose. d. A combination of bFGF and HGF in five-fold dose increased the follicle number as same as in one-fold dose. All of experiments were carried three times; The error bars indicate the SD; *, p<0.05; **, p<0.01; *** p<0.001 (compared with the single growth factor group). NOA = natural ovary aging.
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and bFGF) compared to that in the young mouse group (10%), as shown in Fig. 6C . After injection of a five-fold dose of bFGF and HGF into the ovary of a natural aging mouse model, our results showed that growth factor treatment increased the number of follicles to 19% in the NOA mouse group, 32% in the HGF group, 35% in the bFGF group and 61% in the combination treatment group (HGF and bFGF) compared to that in the young mouse group (Fig. 6D) . In summary, the combination treatment with both growth factors could increase the proliferation rate and inhibit the apoptosis rate of hGCs more effectively than using them singly. Moreover, there was no difference in effectiveness between the one-and five-fold dose groups.
Combination treatment with HGF and bFGF inhibited ROS more effectively in hGCs by upregulating the SIRT1/FOXO1 pathway
To determine how the combination treatment with HGF and bFGF improved the vitality of NOA cells, HGF and bFGF were co-cultured with hGCs for 7 days. The FACS assay results demonstrated that a single growth factor repressed ROS to 24% in the HGF group and 26% in the bFGF group compared to that in the PBS group (51%) (Fig. 7A) . The combination treatment with both growth factors (HGF and bFGF) repressed ROS more powerfully (reaching 16%) than the single growth factor treatments compared to the young hGC group (8%) (Fig. 7A) . The expression levels of enzymes in the antioxidant system were also evaluated. The ELISA results showed that the expression level of SOD was higher (20 U/ mg) after the administration of then combination treatment with both growth factors (HGF Fig. 7 . A combination of bFGF and HGF suppressed ROS via up-regulating SIRT1/FOXO1 pathway in hGCs. a. A combination of bFGF and HGF suppressed ROS more powerful than using them alone in hGCs. b. A combination of bFGF and HGF elevated SOD expression more forceful than one growth factor in hGCs. c. A combination of bFGF and HGF elevated CAT expression more forceful than using them solely in hGCs. d. A combination of bFGF and HGF elevated GR expression to a greater extent than one growth factor in hGCs. e. A combination of bFGF and HGF elevated GPx expression more significantly than using them singly in hGCs. f. A combination of bFGF and HGF promoted the expression of SIRT1 more higher than one growth factor in hGCs. g. A combination of bFGF and HGF restrained acetylation of FOXO1 more effectively than one growth factor in hGCs.
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Cellular Physiology and Biochemistry and bFGF) than the single growth factor treatments (10 U/mg in the HGF group and 12 U/ mg in the bFGF group) in the NOA hCG group compared to that in the young hGC group (25 U/mg), as shown in Fig. 7B . A similar situation was found for CAT, in which the combination treatment with both growth factors (HGF and bFGF) promoted higher expression levels of CAT (8 U/mg) than the single growth factor treatments (4 U/mg in the HGF group and 5 U/mg in the bFGF group) in the NOA hCG group compared to the young hGC group (12 U/mg), as shown in Fig. 7C . In addition, after HGF and bFGF were co-cultured with NOA hCGs, our results demonstrated that the combination treatment (HGF and bFGF) caused a greater increase in the expression level of GR (8 U/mg) than in the HGF group (6 nmol/ min/ml) and in the bFGF group (5 nmol/min/ml) compared to that in the youthful hGC group (13 nmol/min/ml), as shown in Fig. 7D . The combination treatment (HGF and bFGF) also caused a greater increase in the expression level of GPx forcefully (6 nmol/min/ml) than HGF alone (3 nmol/min/ml) or bFGF alone (4 nmol/min/ml) compared to that in the young hGC group (10 nmol/min/ml), as shown in Fig. 7E . Moreover, in the NOA hGC group, the protein assay results showed that treatment with a single growth factor (HGF or bFGF) significantly up-regulated the expression of SIRT1 (45% and 52%, respectively) and FOXO1 (49% and 47%, respectively) compared to the young hGC group. The combination treatment with both growth factors (HGF and bFGF) caused a greater increase in the expression levels of SIRT1 (83%) and FOXO1 (82%) than the single growth factor group (Fig. 7F ). In addition, After growth factor injected into NOA mice ovaries, a combination of bFGF and HGF inhibited ROS level more powerful than using them alone. b. There were parallel effects between one-and five-fold dose growth factor combination group (bFGF and HGF) in promoted the expression level of SOD. c. There were parallel effects between one-and five-fold dose growth factor combination group (bFGF and HGF) in elevated the expression level of CAT. d. There were parallel effects between one-and five-fold dose growth factor combination group (bFGF and HGF) in up-regulated the expression level of GR. e. There were parallel effects between one-and five-fold dose growth factor combination group (bFGF and HGF) in elevated the expression level of GPx. f. In vivo study, combination of bFGF and HGF increased the expression of SIRT1/FOXO1 more higher than one growth factor in NOA mice ovaries. g. A combination of bFGF and HGF repressed acetylation of FOXO1 more effectively than one growth factor in ovary of natural aging mice. All of experiments were carried three times; The error bars indicate the SD; *, p<0.05; **, p<0.01; *** p<0.001 (compared with the single growth factor group). NOA = natural ovary aging. Fig. 9 . A combination of bFGF and HGF were hard to affect the expression of SIRT1/ FOXO1 and ROS level in SIRT1 KDhGCs. a. There is no changed in the expression of SIRT1 and FOXO1 in SIRT1
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KD -hGCs after co-cultured with bFGF and HGF. b. There is no changed in ROS level in SIRT1
KDhGCs after co-cultured with bFGF and HGF. c. There is no changed in SOD expression in SIRT1
KD -hGCs after bFGF and HGF administration. d. There is no changed in CAT expression in SIRT1
KD -hGCs after bFGF and HGF administration. e. There is no changed in GR expression in SIRT1
KD -hGCs after bFGF and HGF administration. f. There is no changed in GPx expression in SIRT1
KD -hGCs after bFGF and HGF administration. g. A proposed model for HGF and bFGF derived from hADSCs improved ovary of natural aging mice through regulating SIRT1/FOXO1 pathway. All of experiments were carried three times; The error bars indicate the SD; *, p<0.05; **, p<0.01; *** p<0.001 (compared with the single growth factor group). NOA = natural ovary aging. treatment with a single growth factor (HGF or bFGF) decreased the protein expression level of ac-FOXO1 to 310% and 330%, respectively, compared to that in the young hGC group (Fig.  7G) . The combination treatment (HGF and bFGF) caused greater inhibition of the expression level of ac-FOXO1 (210%) than the single growth factor treatments (Fig. 7G ).
Combination treatment with HGF and bFGF caused more active repression of ROS in the ovary of the NOA mouse model by up-regulating the SIRT1/FOXO1 pathway To determine how HGF and bFGF restored ovarian function in the NOA mouse model, both were separately injected into mouse ovaries. ELISA analysis demonstrated that combination treatment with both growth factors (HGF and bFGF) inhibited the level of ROS more effectively than single injection of HGF or bFGF (Fig. 8A) . The levels of antioxidative enzymes were also tested in our study. The results revealed that the combination treatment with both growth factors (HGF and bFGF) increased the activities of antioxidant enzymes more powerfully than using them alone (Fig. 8B, 8C, 8D and 8E ). In addition, the protein assay results indicated that a single growth factor (HGF and bFGF) up-regulated the expression of SIRT1 to 40% and 42% and of FOXO1 to 39% and 41%, respectively, compared to that in the young mouse group (Fig. 8F) . In contrast, when HGF and bFGF were injected into the mouse ovary Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry together, we found that the protein expression levels of SIRT1 and FOXO1 were elevated to 67% and 69%, respectively (Fig. 8F) . Simultaneously, injection of a single growth factor (HGF or bFGF) down-regulated the protein expression level of ac-FOXO1 to 320% and 280%, respectively, compared to that in the young mouse group (Fig. 8G) . The combination treatment with both growth factors (HGF and bFGF) decreased the protein expression level of ac-FOXO1 (160%) more forcefully than using a single growth factor (Fig. 8G ).
HGF and bFGF minimally affected the ROS level in hGCs with SIRT1 knockdown
To confirm whether HGF and bFGF repressed ROS through the SIRT1/FOXO1 pathway, RNAi assay was performed in NOA hGCs. The protein assay results revealed that SIRT1 siRNA transfection inhibited the expression of FOXO1 significantly (Fig. 9A) .
Combination treatment with both growth factors caused a greater increase in the protein expression levels of SIRT1 and FOXO1 than using them alone in the control-siRNA group (Fig. 9A) . In addition, regardless of separate treatment with HGF or bFGF, there was no change in the expression levels of SIRT1 and FOXO1 (Fig. 9A) . Similar to the ROS assay results, the FACS assay results showed that the separate administration of HGF and bFGF to the NOA hGC group (SIRT1 knockdown) did not change the ROS level (Fig. 9B) . Furthermore, after HGF and bFGF were co-cultured with NOA hGCs separately or together, we found that there was no significant change in the expression levels of SOD, CAT, GR and GPx (Fig. 9C, 9D , 9E and 9F).
Taken together, the combination treatment with both growth factors (HGF with bFGF) repressed ROS more effectively by up-regulating the SIRT1/FOXO1 pathway in vivo and in vitro.
Discussion
Various stem cells, such as hAECs, BMSCs, human amniotic fluid stem cells and human menstrual blood stem cells, have been used to restore premature ovarian failure [23] . However, whether hADSCs could retard NOA and how hADSCs work are unknown. In a previous study, after hADSC transplantation, the follicle number at four stages (primordial, primary, secondary and antral follicle stages) recovered to nearly normal levels in an NOA mouse model. In addition, we detected the serum index of E2, AMH and FSH, and all of which were also restored to normal levels (Fig. 2) . To bridge the bench-to-bedside gap, the preclinical efficacy of hADSCs for delaying NOA was evaluated by co-culturing hGCs derived from patients with NOA and hADSCs together. Our findings indicated that hADSCs increased the proliferation rate and restored the marker expression levels of hGCs to normal levels (Fig. 3) . Our study provides the first confirmation that hADSCs have the ability to withstand NOA.
Although data from several studies suggest that hADSCs play a pivotal role in wound healing, anti-neural aging and skin aging [21, 22, 27] , few studies have revealed how hADSCs work during this period. Little is known about the mechanism of hADSCs in resisting NOA. According to previous reports, ADSCs can withstand skin aging and improve wound healing by secretory cytokines [28] . Our antibody microarray results revealed that the growth factors HGF and bFGF were secreted from hADSCs at a high level (Fig. 4C) . After hADSC transplantation, HGF and bFGF were highly expressed in the ovary of natural aging mice (Fig.  4D) . Several lines of evidence support that higher levels of HGF and bFGF are secreted by ADSCs [28, 29] . Even so, there has been no reliable evidence that HGF and bFGF function in withstanding NOA. To address this issue further, a combination treatment with both growth factors (HGF and bFGF) was used to clarify this question. After the combination treatment with both growth factors was added to hGCs, our FACS results revealed that HGF and bFGF improved the proliferation rate and reduced the apoptosis rate of hGCs more strongly than using them alone (Fig. 5) . Furthermore, ovarian function assays showed similar results. When HGF and bFGF together were injected into the ovary of natural aging mice, the total follicle number was more notably elevated than when using a single growth factor (Fig. 5) . These current findings are consistent with the results of a previous study that showed that HGF and bFGF promoted cell proliferation and delayed oocyte aging during culture in vitro [30, 31] . A previous report revealed that ovarian aging is associated with oxidative stress [32] . The accumulation of oxidative stress has long-term effects on ovarian follicle depletion. In addition, the cyclical production of ROS may cause cumulative damage to DNA that contributes to ovarian aging [33] . Therefore, whether HGF and bFGF play a central role in retarding ovarian aging by reducing ROS needs to be clarified. At the cellular level, these study results indicate that the combination treatment with both growth factors (HGF and bFGF) inhibited the ROS level significantly and increased the catalytic enzyme activity of the antioxidant system more forcefully than using either of these growth factors alone (Fig.  7A) . Animal experiments also showed similar results. Treatment with a single growth factor inhibited ROS levels slightly more than the combination treatment with both growth factors (HGF and bFGF) in mouse ovary tissue (Fig. 8A) . Our results also showed that HGF and bFGF facilitated the activation of antioxidative enzymes more forcefully than using them singly in ovary tissue (Fig. 7B, 7C , 7D and 7E). These current findings are consistent with the results of a previous study that the accumulation of ROS during a woman's reproductive lifespan might cause oxidative damage to granulosa cells, primordial follicles and ovarian stroma vessels [34] . This finding is also similar to those of previous studies that have suggested that HGF and bFGF have the ability to protect against oxidative injury in different pathways [35, 36] .
However, the regulatory mechanisms of attenuated ROS levels remain elusive. According to the literature, sirtuins are regarded as anti-aging or longevity proteins [12] . Moreover, FOXO proteins influence a range of functions, including cell differentiation, metabolism, cycle, apoptosis, stress resistance, DNA repair, and aging [37] . In our study, the protein assay results revealed that the combination treatment with both growth factors (HGF and bFGF) increased the expression levels of SIRT1 and FOXO1 more significantly than using them solely in vivo and in vitro (Fig. 7F and 8F ). In addition, the combination treatment with both growth factors (HGF and bFGF) greatly reduced the expression level of ac-FOXO1 (Fig. 7G  and 8G ). Several lines of evidence support this result and indicate that SIRT1 plays a key role in the adaptive responses of cells to a variety of oxidative stressors by deacetylating several FOXO members [17, 38] . Earlier research also revealed that FOXO1 is one of the FOXO proteins and that its transcriptional activity is modulated by SIRT1 [39] . The SIRT1/FOXO1 pathway is known to be a crucial regulator of apoptosis and oxidative stress resistance [40] .
Conclusion
In summary, we investigated the interaction between hADSCs and NOA for the first time. The results of the present study provide insight into the mechanism by which hADSCs delay NOA by secreting HGF and bFGF. Furthermore, our present study revealed that the combination treatment with both growth factors (HGF and bFGF) inhibited ROS by upregulating SIRT1 and FOXO1 expression and down-regulating FOXO1 acetylation. Therefore, we suggest that hADSCs improve the ovarian function of natural aging by secreting HGF and bFGF and that the combination treatment with both growth factors inhibits ROS through activation of the SIRT1/FOXO1 pathway (Fig. 9G) . This discovery has important implications for understanding the molecular mechanism by which growth factors promote the ovarian function of natural aging. Moreover, this discovery suggests that HGF and bFGF may serve as a novel, safer and efficacious therapeutic schedule to resist NOA and improve female reproductive health.
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